Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZBR Regimen in Untreated Waldenström Macroglobulinemia
NCT07259122Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07259122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259122.